Aslan Other Current Liab vs Non Currrent Assets Other Analysis

ASLN Stock

USD 0.42 0.03 6.67%

Aslan Pharmaceuticals financial indicator trend analysis is way more than just evaluating Aslan Pharmaceuticals prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Aslan Pharmaceuticals is a good investment. Please check the relationship between Aslan Pharmaceuticals Other Current Liab and its Non Currrent Assets Other accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

Other Current Liab vs Non Currrent Assets Other

Other Current Liab vs Non Currrent Assets Other Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Aslan Pharmaceuticals Other Current Liab account and Non Currrent Assets Other. At this time, the significance of the direction appears to have very week relationship.

The correlation between Aslan Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is 0.24. Overlapping area represents the amount of variation of Other Current Liab that can explain the historical movement of Non Currrent Assets Other in the same time period over historical financial statements of Aslan Pharmaceuticals Ltd, assuming nothing else is changed. The correlation between historical values of Aslan Pharmaceuticals' Other Current Liab and Non Currrent Assets Other is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Current Liab of Aslan Pharmaceuticals Ltd are associated (or correlated) with its Non Currrent Assets Other. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Non Currrent Assets Other has no effect on the direction of Other Current Liab i.e., Aslan Pharmaceuticals' Other Current Liab and Non Currrent Assets Other go up and down completely randomly.

Correlation Coefficient

0.24

Relationship Direction	Positive
Relationship Strength	Very Weak

View All Relationships

Other Current Liab

Non Currrent Assets Other

Assets that are not physical or tangible, expected to provide value for more than one year, and not easily converted into cash, such as long-term investments or patents.

Most indicators from Aslan Pharmaceuticals' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Aslan Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

As of the 27th of April 2024, Sales General And Administrative To Revenue is likely to grow to 1.21, while Selling General Administrative is likely to drop about 9.6 M.

Aslan Pharmaceuticals fundamental ratios Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Long Term Debt	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Short Long Term Debt	Total Current Assets	Short Term Debt
Total Assets		0.63	0.18	0.46	0.87	0.39	0.3	-0.83	-0.51	0.51	0.98	0.24	0.31	0.11	-0.06	0.98	0.63	0.66	-0.22	0.63	0.7	0.02	0.3	-0.63	0.97	-0.71
Short Long Term Debt Total	0.63		0.3	0.87	0.39	-0.23	0.33	-0.23	-0.89	0.81	0.62	-0.02	0.61	-0.02	-0.19	0.62	0.8	0.93	-0.06	0.92	0.95	0.36	0.33	-0.45	0.65	-0.5
Other Current Liab	0.18	0.3		0.44	0.12	0.11	0.5	0.06	-0.46	0.55	0.1	0.32	0.24	0.55	0.06	0.1	0.49	0.44	-0.18	0.16	0.4	0.04	0.5	-0.6	0.11	-0.53
Total Current Liabilities	0.46	0.87	0.44		0.27	-0.07	0.34	-0.06	-0.81	0.95	0.43	0.09	0.78	-0.01	-0.21	0.43	0.75	0.83	-0.2	0.76	0.83	0.28	0.34	-0.48	0.45	-0.46
Total Stockholder Equity	0.87	0.39	0.12	0.27		0.63	0.42	-0.85	-0.29	0.34	0.84	0.33	0.11	0.18	-0.33	0.84	0.62	0.48	-0.55	0.31	0.54	-0.43	0.42	-0.54	0.83	-0.61
Net Tangible Assets	0.39	-0.23	0.11	-0.07	0.63		0.28	-0.63	0.19	0.02	0.41	0.05	-0.09	-0.08	-0.12	0.41	0.14	0.0	-0.55	-0.22	-0.04	-0.59	0.28	-0.39	0.39	-0.38
Property Plant And Equipment Net	0.3	0.33	0.5	0.34	0.42	0.28		-0.15	-0.47	0.23	0.29	0.06	0.04	0.4	-0.28	0.29	0.72	0.41	-0.61	0.07	0.46	-0.43	1.0	-0.68	0.29	-0.65
Net Debt	-0.83	-0.23	0.06	-0.06	-0.85	-0.63	-0.15		0.02	-0.13	-0.86	-0.06	-0.11	0.01	-0.08	-0.86	-0.3	-0.28	0.12	-0.22	-0.31	0.13	-0.15	0.42	-0.85	0.51
Retained Earnings	-0.51	-0.89	-0.46	-0.81	-0.29	0.19	-0.47	0.02		-0.75	-0.49	-0.03	-0.36	-0.03	0.23	-0.49	-0.85	-0.92	0.23	-0.84	-0.92	-0.21	-0.47	0.59	-0.51	0.6
Accounts Payable	0.51	0.81	0.55	0.95	0.34	0.02	0.23	-0.13	-0.75		0.46	0.18	0.78	0.02	-0.25	0.46	0.68	0.8	-0.21	0.75	0.8	0.24	0.23	-0.43	0.48	-0.41
Cash	0.98	0.62	0.1	0.43	0.84	0.41	0.29	-0.86	-0.49	0.46		0.03	0.31	-0.05	-0.03	1.0	0.59	0.64	-0.16	0.65	0.67	0.06	0.29	-0.59	1.0	-0.67
Non Current Assets Total	0.24	-0.02	0.32	0.09	0.33	0.05	0.06	-0.06	-0.03	0.18	0.03		-0.06	0.79	-0.09	0.03	0.22	0.04	-0.27	-0.14	0.11	-0.23	0.06	-0.26	0.02	-0.25
Non Currrent Assets Other	0.31	0.61	0.24	0.78	0.11	-0.09	0.04	-0.11	-0.36	0.78	0.31	-0.06		-0.11	-0.07	0.31	0.28	0.42	0.08	0.55	0.44	0.43	0.04	-0.08	0.33	-0.07
Other Assets	0.11	-0.02	0.55	-0.01	0.18	-0.08	0.4	0.01	-0.03	0.02	-0.05	0.79	-0.11		0.11	-0.05	0.26	0.0	-0.13	-0.27	0.07	-0.14	0.4	-0.39	-0.06	-0.37
Long Term Debt	-0.06	-0.19	0.06	-0.21	-0.33	-0.12	-0.28	-0.08	0.23	-0.25	-0.03	-0.09	-0.07	0.11		-0.03	-0.32	-0.18	0.79	-0.17	-0.28	0.67	-0.28	-0.22	-0.04	-0.21
Cash And Short Term Investments	0.98	0.62	0.1	0.43	0.84	0.41	0.29	-0.86	-0.49	0.46	1.0	0.03	0.31	-0.05	-0.03		0.59	0.64	-0.16	0.65	0.67	0.06	0.29	-0.59	1.0	-0.67
Common Stock Total Equity	0.63	0.8	0.49	0.75	0.62	0.14	0.72	-0.3	-0.85	0.68	0.59	0.22	0.28	0.26	-0.32	0.59		0.9	-0.49	0.6	0.92	-0.13	0.72	-0.76	0.6	-0.78
Common Stock Shares Outstanding	0.66	0.93	0.44	0.83	0.48	0.0	0.41	-0.28	-0.92	0.8	0.64	0.04	0.42	0.0	-0.18	0.64	0.9		-0.21	0.85	0.98	0.2	0.41	-0.64	0.67	-0.68
Non Current Liabilities Total	-0.22	-0.06	-0.18	-0.2	-0.55	-0.55	-0.61	0.12	0.23	-0.21	-0.16	-0.27	0.08	-0.13	0.79	-0.16	-0.49	-0.21		0.04	-0.27	0.87	-0.61	0.27	-0.16	0.25
Other Current Assets	0.63	0.92	0.16	0.76	0.31	-0.22	0.07	-0.22	-0.84	0.75	0.65	-0.14	0.55	-0.27	-0.17	0.65	0.6	0.85	0.04		0.85	0.44	0.07	-0.3	0.67	-0.35
Other Stockholder Equity	0.7	0.95	0.4	0.83	0.54	-0.04	0.46	-0.31	-0.92	0.8	0.67	0.11	0.44	0.07	-0.28	0.67	0.92	0.98	-0.27	0.85		0.14	0.46	-0.61	0.69	-0.65
Total Liab	0.02	0.36	0.04	0.28	-0.43	-0.59	-0.43	0.13	-0.21	0.24	0.06	-0.23	0.43	-0.14	0.67	0.06	-0.13	0.2	0.87	0.44	0.14		-0.43	0.02	0.07	0.01
Property Plant And Equipment Gross	0.3	0.33	0.5	0.34	0.42	0.28	1.0	-0.15	-0.47	0.23	0.29	0.06	0.04	0.4	-0.28	0.29	0.72	0.41	-0.61	0.07	0.46	-0.43		-0.68	0.29	-0.65
Short Long Term Debt	-0.63	-0.45	-0.6	-0.48	-0.54	-0.39	-0.68	0.42	0.59	-0.43	-0.59	-0.26	-0.08	-0.39	-0.22	-0.59	-0.76	-0.64	0.27	-0.3	-0.61	0.02	-0.68		-0.58	0.99
Total Current Assets	0.97	0.65	0.11	0.45	0.83	0.39	0.29	-0.85	-0.51	0.48	1.0	0.02	0.33	-0.06	-0.04	1.0	0.6	0.67	-0.16	0.67	0.69	0.07	0.29	-0.58		-0.67
Short Term Debt	-0.71	-0.5	-0.53	-0.46	-0.61	-0.38	-0.65	0.51	0.6	-0.41	-0.67	-0.25	-0.07	-0.37	-0.21	-0.67	-0.78	-0.68	0.25	-0.35	-0.65	0.01	-0.65	0.99	-0.67

Click cells to compare fundamentals

Aslan Pharmaceuticals Account Relationship Matchups

Aslan Pharmaceuticals fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	23.3M	16.1M	94.5M	61.2M	24.6M	45.1M
Short Long Term Debt Total	18.4M	19.3M	31.1M	37.6M	26.8M	19.9M
Other Current Liab	3.2M	267K	223.4K	2.4M	3.2M	2.0M
Total Current Liabilities	5.4M	10.7M	6.4M	23.2M	13.1M	8.8M
Total Stockholder Equity	(1.7M)	(10.5M)	57.3M	8.4M	(13.3M)	(12.6M)
Other Liab	4.8M	8.9M	13.4M	112.0K	128.8K	122.3K
Net Tangible Assets	(50.3M)	(10.5M)	57.3M	8.4M	7.5M	7.1M
Property Plant And Equipment Net	766.2K	475.9K	232.7K	292.7K	259.2K	366.0K
Net Debt	(3.8M)	4.9M	(59.1M)	(19.3M)	5.6M	5.9M
Retained Earnings	(179.5M)	(195.7M)	(227.0M)	(278.4M)	(321.1M)	(305.0M)
Accounts Payable	1.9M	2.3M	3.1M	12.8M	7.9M	4.4M
Cash	22.2M	14.3M	90.2M	56.9M	21.3M	40.5M
Non Current Assets Total	1.1M	579.4K	737.4K	307.2K	496.5K	471.7K
Non Currrent Assets Other	108.1K	103.3K	10.0K	8.6M	1.7K	1.6K
Other Assets	7.1M	5.3M	103.3K	1.0	1.15	1.09
Long Term Debt	17.6M	15.2M	30.9M	29.7M	24.8M	23.6M
Cash And Short Term Investments	22.2M	14.3M	90.2M	56.9M	21.3M	40.5M
Common Stock Total Equity	43.8M	51.6M	61.4M	61.8M	71.1M	40.0M
Common Stock Shares Outstanding	6.5M	7.7M	13.0M	13.9M	16.4M	8.4M
Liabilities And Stockholders Equity	23.3M	16.1M	94.5M	61.2M	24.6M	45.1M
Non Current Liabilities Total	18.6M	15.6M	30.9M	29.7M	24.8M	19.4M
Other Current Assets	68.9K	649.1K	3.6M	4.0M	2.7M	2.8M
Other Stockholder Equity	116.5M	123.6M	221.5M	223.9M	219.8M	127.5M
Total Liab	24.0M	26.2M	37.2M	52.8M	37.9M	35.5M
Property Plant And Equipment Gross	766.2K	475.9K	232.7K	292.7K	259.3K	366.0K
Total Current Assets	22.3M	15.5M	93.8M	60.9M	24.1M	41.9M
Short Term Debt	264.5K	3.8M	199.1K	8.0M	2.0M	3.5M
Intangible Assets	23.1M	2.8K	160.0	5.8M	6.7M	4.8M
Common Stock	51.6M	61.4M	61.8M	63.0M	63.9M	48.9M
Property Plant Equipment	23.0M	475.9K	232.7K	292.7K	263.5K	250.3K
Capital Lease Obligations	755.4K	552.8K	199.1K	215.7K	226.2K	238.2K
Non Current Liabilities Other	161.8K	289.6K	447.2K	112.0K	128.8K	185.3K
Net Invested Capital	16.0M	8.2M	88.2M	45.8M	13.3M	12.6M
Net Working Capital	16.9M	4.8M	87.4M	37.7M	11.0M	10.5M

Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Aslan Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Aslan Pharmaceuticals' short interest history, or implied volatility extrapolated from Aslan Pharmaceuticals options trading.

Pair Trading with Aslan Pharmaceuticals

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Aslan Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Aslan Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

The ability to find closely correlated positions to Aslan Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Aslan Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Aslan Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Aslan Pharmaceuticals Ltd to buy it.

The correlation of Aslan Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Aslan Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Aslan Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Aslan Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Aslan Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Aslan Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Aslan Pharmaceuticals Ltd Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Aslan Pharmaceuticals Ltd Stock:

How To Invest In Aslan

Details

Is Aslan Stock a good investment?

Details

What is Aslan Pharmaceuticals' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aslan Pharmaceuticals Ltd. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in bureau of economic analysis.

You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Aslan Stock analysis

When running Aslan Pharmaceuticals' price analysis, check to measure Aslan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aslan Pharmaceuticals is operating at the current time. Most of Aslan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Aslan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aslan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Aslan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

	Share Portfolio Track or share privately all of your investments from the convenience of any device
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets
	Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges
	Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments
	Fundamental Analysis View fundamental data based on most recent published financial statements
	Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity

Is Aslan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aslan Pharmaceuticals. If investors know Aslan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aslan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(2.75)

Revenue Per Share

0.729

Return On Assets

(0.64)

Return On Equity

(4.27)

The market value of Aslan Pharmaceuticals is measured differently than its book value, which is the value of Aslan that is recorded on the company's balance sheet. Investors also form their own opinion of Aslan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Aslan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aslan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Aslan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Aslan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aslan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aslan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Aslan Other Current Liab vs Non Currrent Assets Other Analysis

Other Current Liab vs Non Currrent Assets Other

Other Current Liab vs Non Currrent Assets Other Correlation Analysis

Correlation Coefficient

Other Current Liab

Non Currrent Assets Other

Aslan Pharmaceuticals fundamental ratios Correlations

Aslan Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Aslan Pharmaceuticals fundamental ratios Accounts

Pair Trading with Aslan Pharmaceuticals

Complementary Tools for Aslan Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Property Plant And Equipment Gross	+ 1.0	Property Plant And Equipment Net
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash And Short Term Investments
Short Term Debt	+ 0.99	Short Long Term Debt
Cash	+ 0.98	Total Assets

Other Stockholder Equity	- 0.92	Retained Earnings
Common Stock Shares Outstanding	- 0.92	Retained Earnings
Retained Earnings	- 0.89	Short Long Term Debt Total
Cash And Short Term Investments	- 0.86	Net Debt
Cash	- 0.86	Net Debt
Common Stock Total Equity	- 0.85	Retained Earnings